Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Human aldo-keto reductases (AKR) of the 1A, 1B, 1C and 1D subfamilies are involved in the pre-receptor regulation of nuclear (steroid hormone and orphan) receptors by regulating the local concentrations of their lipophilic ligands. AKR1C3 is one of the most interesting isoforms. It was cloned from human prostate and the recombinant protein was found to function as a 3-, 17- and 20-ketosteroid reductase with a preference for the conversion of Delta4-androstene-3,17-dione to testosterone implicating this enzyme in the local production of active androgens within the prostate. Using a validated isoform specific real-time RT-PCR procedure the AKR1C3 transcript was shown to be more abundant in primary cultures of epithelial cells than stromal cells, and its expression in stromal cells increased with benign and malignant disease. Using a validated isoform specific monoclonal Ab, AKR1C3 protein expression was also detected in prostate epithelial cells by immunoblot analysis. Immunohistochemical staining of prostate tissue showed that AKR1C3 was expressed in adenocarcinoma and surprisingly high expression was observed in the endothelial cells. These cells are a rich source of prostaglandin G/H synthase 2 (COX-2) and vasoactive prostaglandins (PG) and thus the ability of recombinant AKR1C enzymes to act as PGF synthases was compared. AKR1C3 had the highest catalytic efficiency (kcat/Km) for the 11-ketoreduction of PGD2 to yield 9alpha,11beta-PGF2 raising the prospect that AKR1C3 may govern ligand access to peroxisome proliferator activated receptor (PPARgamma). Activation of PPARgamma is often a pro-apoptotic signal and/or leads to terminal differentiation, while 9alpha,11beta-PGF2 is a pro-proliferative signal. AKR1C3 is potently inhibited by non-steroidal anti-inflammatory drugs suggesting that the cancer chemopreventive properties of these agents may be mediated either by inhibition of AKR1C3 or COX. To discriminate between these effects we developed potent AKR1C inhibitors based on N-phenylanthranilic acids that do not inhibit COX-1 or COX-2. These compounds can now be used to determine the role of AKR1C3 in producing two proliferative signals in the prostate namely testosterone and 9alpha,11beta-PGF2.
Penning
Trevor M
TM
Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104-6084, USA. penning@pharm.med.upenn.edu
Steckelbroeck
Stephan
S
Bauman
David R
DR
Miller
Meredith W
MW
Jin
Yi
Y
Peehl
Donna M
DM
Fung
Kar-Ming
KM
Lin
Hseuh-Kung
HK
D015096:3-Hydroxysteroid Dehydrogenases / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000502:physiology; D000074425:Aldo-Keto Reductase Family 1 Member C3; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D015237:Dinoprost / Q000096:biosynthesis; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D012739:Gonadal Steroid Hormones / Q000096:biosynthesis / Q000378:metabolism; D006801:Humans; D006911:Hydroxyprostaglandin Dehydrogenases / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000502:physiology; D008297:Male; D011467:Prostate / Q000201:enzymology; D011469:Prostatic Diseases / Q000201:enzymology* / Q000235:genetics; D013329:Structure-Activity Relationship; D013739:Testosterone / Q000096:biosynthesis; D014158:Transcription, Genetic
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004791:Enzyme Inhibitors; D012739:Gonadal Steroid Hormones; D013739:Testosterone; D015237:Dinoprost; D015096:3-Hydroxysteroid Dehydrogenases; D006911:Hydroxyprostaglandin Dehydrogenases; C487341:AKR1C3 protein, human; D000074425:Aldo-Keto Reductase Family 1 Member C3